Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection; (NOTE: a designation of type I or type II should be made by the local pathologist if possible); mixed histologies containing type I or type II will be allowed provided that they contain >= 50% of the papillary component
Patients must have tissue available and be willing to submit for independent pathologic review in order to classify type I versus type II papillary disease
Type 1 or 2 diabetes requiring anti-hyperglycemic medication (e.g. metformin, glipizide, insulin)
Patients with Diabetes Type I or uncontrolled Type II as judged by the Investigator
Diabetes mellitus type 1
Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.
Type I or type II diabetes, or Hgb A1c > 6.5%
Type 1 or Type 2 diabetes mellitus requiring insulin at study entry
EXCLUSION - INFUSION: Uncontrolled autoimmune disease needing systemic steroids or steroid sparing agents except for hypothyroidism or type I diabetes
Participant has a concurrent diagnosis of type I or type II diabetes that is being treated with insulin or an oral antidiabetic agent; (participants whose type II diabetes is controlled with diet and/or exercise alone are eligible provided they meet all other eligibility criteria)
Part B: Must have a type of malignancy that is being studied.
Patients may have neurofibromatosis type 1 or 2
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible
Participants with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone or participants with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study with approval by the medical monitor
Uncontrolled diabetes mellitus. Patients with Type II diabetes are eligible if they require only oral hypoglycemic agents and fasting blood glucose level is ?120. Patients with Type I diabetes are eligible if their glycosylated hemoglobin (HbAlc) is ?7.
Uncontrolled (per investigator judgment) type I or type II diabetes mellitus.
Patients with uncontrolled type 1 diabetes mellitus. If on a stable insulin regimen may be eligible, after discussion with principal investigator.
History of multiple sclerosis, type 1 diabetes mellitus (DM) or Guillain-Barre syndrome
Patients with certain diseases such as active autoimmune disease, type I diabetes, hypothyroidism that needs hormone replacement, active infection, psychiatric disorder.
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible
Has a confirmed diagnosis of type 1 diabetes or type 2 diabetes that has been diagnosed by an HbA1c ? 6.5, or is on any hypoglycemic medications (insulin, metformin, etc)
FOR ALL PHASES (Ib AND II): Type I diabetes or patients on insulin therapy are not allowed; uncontrolled type II diabetes not allowed (glycosylated hemoglobin [HbA1c] > 7.5)
History of autoimmune disease except for controlled, treated thyroidism or Type 1 diabetes
Patients with certain diseases such as active autoimmune disease, type I diabetes, hypothyroidism that needs hormone replacement, active infection, psychiatric disorder
Tumor type:
Subjects with uncontrolled type I or II diabetes mellitus
Patients with auto-immune disease, with the exception of type I diabetes or treated hypothyroidism.
Type 1 diabetes mellitus or type 2 diabetes mellitus actively receiving treatment
Insulin-dependent diabetes; patients with type II diabetes must meet the inclusion criteria outlined above
History of autoimmune disease except treated/stable hypothyroidism, Type 1 diabetes mellitus, and protocol-specified dermatologic conditions
Patient with an established diagnosis of diabetes mellitus type I or uncontrolled type II
Patients with active autoimmune disease, with exceptions of vitiligo, type I diabetes mellitus, hypothyroidism and psoriasis.
Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
Patients with uncontrolled type 1 or type 2 diabetes; patients with an elevated risk of hyperglycemia should be excluded from study
Diabetic patients (type I or II diabetes mellitus) must have baseline hemoglobin (Hb)A1c levels NOT higher than 8.5% at study entry
For the Diabetes Expansion Cohort - Subjects with known history of type 2 diabetes\n             mellitus that are well-controlled on a stable dose of oral anti-diabetic agents such\n             as metformin and/or sulfonylureas for 4 weeks prior to screening.
For the Diabetes Expansion Cohort - Subjects who have type 1 diabetes mellitus,\n             maturity onset diabetes of the young, hyperglycemia due to reasons other than type 2\n             diabetes mellitus.
Patients must not have type I or II diabetes that requires anti-hyperglycemic medication
History of autoimmune disease except controlled/treated hypothyroidism, type 1 diabetes mellitus, or certain skin disorders
Type 1 diabetes or uncontrolled Type 2 diabetes
Patients with an established diagnosis of diabetes mellitus type I or not controlled type II
Subjects with uncontrolled type I or type II diabetes mellitus (defined as HgbA1c > 8).
Patients with uncontrolled Diabetes Type I or Type II
Type 1 or Type 2 diabetes mellitus requiring anti-hyperglycemic medications
Histologically or cytologically confirmed recurrent or metastatic SCCHN\r\n* All primary sites are eligible excluding World Health Organization (WHO) type III or Epsteinâ€“Barr virus (EBV) nasopharyngeal (WHO type I and WHO type II allowed as long as they are EBV negative)
history of Diabetes Mellitus, type 1 or type 2,
Epithelial type
Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.
Patients with type II diabetes currently already on metformin
Type I or II diabetes mellitus with HbA1c > 8.5% at Screening.
Known history of autoimmune disease (with the exceptions of medically-controlled hypothyroidism and type I diabetes mellitus)
Patients with type II diabetes mellitus that is well controlled by dietary measures alone and have a hemoglobin A1c (HgA1c) < 8% are eligible to participate; patients found to have a fasting glucose >= 7 mmol/L (>= 126 mg/dL) or glycosylated hemoglobin > 8% (64 mmol/mol) at screening should be assessed for appropriate management according to local policy; those in whom dietary measures alone provide good diabetic control will be eligible for inclusion; type I or II diabetes mellitus requiring either insulin or oral hypoglycemics for routine management will be excluded
Patients with diabetes type I or uncontrolled type II (HbA1c > 8 % assessed locally) as judged by the investigator
History of type I diabetes mellitus; if a patient has type II diabetes, they must have a hemoglobin (hemoglobin A1C) =< 8%; patients with a screening fasting glucose > 120 mg/dL will be excluded
Subjects with Type II diabetes are only allowed if their HbA1C is less than 8 percent at study entry.
Previously diagnosed diabetes mellitus Type I. Subjects with Type II diabetes are allowed if entry criteria are fulfilled
History of Type 1 or Type 2 diabetes requiring regular medication
Patients must not have active or history of clinically significant autoimmune disorders/conditions including type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria
Patients must not have active or history of clinically significant autoimmune disease, defined as requiring systemic therapy, such as type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria
Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.
Type I or II diabetes mellitus with HbA1c > 8.5% at screening (modified by amendment 1)
Patient with type 1 diabetes mellitus or not adequately controlled type 2 diabetes mellitus
Type 1 diabetes or uncontrolled Type 2 diabetes
History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes
Type 1 or 2 diabetes requiring antihyperglycemic medication
Patients with Diabetes Type I or uncontrolled Type II (HbA1c > 59 mmol/mol assessed locally) as judged by the Investigator
Subject has Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus and currently being treated with insulin or sulfonylureas.
Fracture is closed, Gustilo Type I or II.
DONOR: History of type I or type II diabetes mellitus
Subjects with type 1 or type 2 diabetes mellitus
Diabetes mellitus, unless it is type II diabetes adequately controlled with anti-diabetic agents (A1c < 7)
Type 1 or Type 2 diabetes
Type I Diabetes
Type 1 or 2 diabetes mellitus
History of Type I or Type II diabetes mellitus requiring insulin
Type I diabetes
Type II diabetes requiring chronic therapy with insulin
History of Type 1 or 2 diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose ?160 mg/dL at the prestudy visit. If a diabetic cohort is enrolled, only subjects with a medical history of controlled Type 1 or 2 diabetes mellitus will be enrolled in the cohort.
Type 1 or 2 diabetes requiring anti-hyperglycemic medication
Patients with a known history of type 1 or type 2 diabetes mellitus
Type I diabetes or uncontrolled type II diabetes
Type 1 or type 2 diabetes
Type 1 diabetes
type 1 diabetes
Reported current diagnosis or history of type I diabetes or type 2 diabetes.
Any type of ostomy
Type I diabetes mellitus
Any disease type
Group III: Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled type II diabetes (glucose levels < 250) may be included
Diabetes type I or II, or currently on medications to reduce blood sugar
Participants with type 2 diabetes, documented stomach ulcers and pulmonary embolism
Patients with diabetes type 1 or uncontrolled type II (HbA1c > 8% assessed locally)
History of autoimmune disease. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.
